A Prospective Study of Nut Consumption and Risk of Primary Hepatocellular Carcinoma in the U.S. Women and Men

Jing Sui1,2, Wanshui Yang2,3, Yanan Ma2,4, Tricia Y. Li2, Tracey G. Simon5,6,7, Jeffrey A. Meyerhardt8, Geyu Liang1, Edward L. Giovannucci9,10, Andrew T. Chan2,6,7, and Xuehong Zhang2

Abstract

Although increasing evidence suggests a potential beneficial effect of nut consumption on various diseases, no epidemiologic study has yet examined the association between nut consumption and risk of hepatocellular carcinoma (HCC). We prospectively examined this association in 88,783 women from the Nurses' Health Study and 51,492 men from the Health Professionals Follow-up Study. Nut consumption was assessed every 4 years using validated food frequency questionnaires. Multi-variable HRs and 95% confidence intervals (95% CI) were estimated using Cox proportional hazards regression models after adjusting for HCC risk factors. After an average of 27.9 years of follow-up, we identified a total of 162 incident HCC cases. Higher total nut consumption was not significantly associated with HCC risk (the highest vs. lowest tertile intake, HR, 0.84; 95% CI, 0.56–1.26). For the same comparison, higher tree nut consumption was associated with a lower HCC risk (HR, 0.64; 95% CI, 0.43–0.95). We found nonsignificant inverse associations with consumption of walnuts, peanuts, and peanut butter. Overall, nut consumption was not strongly associated with HCC risk. There was a suggestive inverse association with tree nut consumption. Future studies should carefully consider hepatitis B or C virus infections and examine these associations in other racial/ethnic groups.

Introduction

Worldwide, liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related death (1). The predominant histologic form of primary liver cancer is hepatocellular carcinoma (HCC) (2). In the United States, HCC has one of the most rapidly increasing incidence rates among both women and men (3). In addition, the median survival time after HCC diagnosis remains less than 1 year (4). Currently, the major known risk factors for HCC are hepatitis B or hepatitis C virus (HBV/HCV) infections, aflatoxin contamination, smoking, obesity, type II diabetes, nonalcoholic fatty liver diseases (NAFLD), and heavy alcohol drinking (5). Other dietary factors might play an important role in HCC development (6), but the current epidemiologic studies on diet and HCC risk are very limited.

Nuts are good sources of unsaturated fatty acids, vitamins, folate, fiber, minerals, and other bioactive compounds (7, 8). Nut consumption might influence risk of HCC through mechanisms related to insulin sensitivity and inflammation. For example, higher nut consumption may cause sustained weight loss and improved insulin sensitivity (9), and was inversely associated with circulating levels of IL6 and C-reactive protein (10), higher levels of which were associated with higher HCC risk (11, 12). Furthermore, higher nut consumption was associated with a lower risk of type II diabetes (13), a risk factor for HCC (14, 15). Despite this evidence, no epidemiologic study to our knowledge has

Note: Supplementary data for this article are available at Cancer Prevention Research Online (http://cancerprevention.aacrjournals.org/).

Corresponding Author: Xuehong Zhang, Brigham and Women’s Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA 02115. Phone: 617-525-0342; Fax: 617-525-2008; E-mail: xuehong.zhang@channing.harvard.edu

Cancer Prev Res 2019;12:367-74

doi: 10.1158/1940-6207.CAPR-18-0511

©2019 American Association for Cancer Research.

www.aacrjournals.org
yet examined the association between nut consumption and HCC risk.

We hypothesized that higher nut consumption may decrease risk of developing HCC. We tested this hypothesis by utilizing two large U.S.-based prospective cohort studies of women (the Nurses’ Health Study, NHS) and men (the Health Professionals Follow-up Study, HPFS).

Materials and Methods

Study population

For this study, we included two ongoing prospective cohort studies: the NHS, which consists of 121,700 female nurses 30–55 years of age in 1976; and the HPFS, which consists of 51,529 male health professionals 40–75 years of age in 1986 (16, 17). In each cohort, the follow-up questionnaires were sent biennially to collect information on demographics, medical history, lifestyles, as well as health conditions. The follow-up rate has been over 90% in each cohort. This study was approved by the Institutional Review Boards of Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health (Boston, MA).

Dietary assessments

We used food frequency questionnaires (FFQ) to assess nut consumption and other dietary factors such as alcohol and coffee consumption (18). Briefly, the FFQs were administered to NHS participants in 1980, 1984, 1986, and every 4 years thereafter. A similar FFQ was administered to HPFS participants in 1986 and every 4 years thereafter. In the FFQ, participants were asked how often on average they have had consumed a serving of nuts [serving size, 28 g (1 oz)] during the preceding year with nine responses ranging from never or less than once a month to more than six times a day. In 1986 and subsequent FFQs in each cohort, the question about nuts was split into peanuts and other nuts. Starting in 1998 in each cohort, walnut consumption was collected. Consistent with previous studies from the same cohorts (19, 20), we defined total nut consumption as the intake of peanuts, walnuts (if available), and other nuts. "Other nuts" was defined as all types of tree nuts, including walnuts, hazelnuts, almonds, macadamias, pecans, cashews, and pistachios (not including peanuts, which are legumes, but with a similar fatty acid and nutrient profile as tree nuts). Nut intake was measured with reasonable validity, with the corrected correlation coefficient of 0.75 comparing the intake from the FFQ and those from the four 1-week dietary records (21).

Assessments of covariates

We also inquired information on factors such as age, race, height, body weight, physical activity, total calorie intake, type II diabetes, Alternative Healthy Eating Index-2010 (AHEI-2010), aspirin use, and smoking status. Participants reported the average amount of time spent per week during the previous year participating in each of the following specific activities: walking; jogging; running; bicycling; lap swimming; racquet sports (tennis, squash, and racquetball); and calisthenics/rowing, and other aerobics. Each specific activity was assigned a metabolic equivalent task (MET) score (22), and participants were assigned a weekly physical activity score expressed in MET hours per week. Total physical activity was calculated by summing the MET-hours per week across all activities reported by the participant. The AHEI-2010 was based on foods and nutrients predictive of chronic disease risk and was used to clarify the role of additional dietary factors in the development of chronic disease (23). The AHEI-2010 consists of 11 components [vegetables, fruit, whole grains, nuts and legumes, sugar-sweetened beverages and fruit juice, red and processed meat, trans fat, long-chain omega-3 fats, polyunsaturated fatty acids (PUFA), sodium, and alcohol; ref. 24]. Each component ranges from 0 to 10 points with a total score ranging from 0 to 110 points.

Ascertained of incident HCC

In each cohort, participants who reported a diagnosis of HCC on the biennial questionnaire were asked for written permission to obtain their medical records. Considering potential unreported cancer cases, we further searched State Cancer Registries and the National Death Index (25). For all deaths attributable to HCC, we contacted next of kin for the deceased participants to obtain permission to review the medical records. Physicians who were blinded to exposure status (i.e., nut consumption) reviewed medical records to confirm the incident of HCC. For all HCC cases, physicians also extracted information on the histologic subtypes of the cancer (e.g., HCC vs. intrahepatic cholangiocarcinoma), underlying cirrhosis diagnosed by histopathology or by appropriate cross-sectional imaging, and HBV/HCV infection status. Additional data on HBV/HCV infection status were also available from a nested case–control study of HCC in the NHS/HPFS, which were derived from laboratory blood tests (26).

Statistical analyses

In this study, we defined baseline as 1980 for women (NHS) and 1986 for men (HPFS), when nut consumption data was first available. We excluded the participants with a history of cancer (except for nonmelanoma skin cancer) at baseline, or with implausibly energy intake, or missing data on nut consumption. After exclusions, we included 88,783 women in the NHS and 51,492 men in the HPFS for this analysis. We calculated each individual’s person-time from the date of the return of baseline questionnaire to the date of diagnosis of HCC, date of death, loss to follow-up, or the end of follow up (June 1, 2012 for the NHS and January 31, 2012 for the HPFS), whichever came first.
To better represent long-term diet and minimize within-person variations, we calculated cumulative average of nut consumption and other dietary factors from each FFQ (20). Nut consumption was energy adjusted using the residual method (27). Multivariable HRs and 95% confidence intervals (CI) of HCC by the gender-specific tertiles of energy-adjusted total nut intake were estimated using time-varying Cox proportional hazard regression models after adjusting for most known HCC risk factors. We also performed separate analyses for peanuts, tree nuts, walnuts, and peanut butter. Cox regression models were stratified by age in months and year of questionnaire return, enabling fine control of confounding for age and secular trends. In multivariable analyses, we adjusted for race, physical activity, body mass index (BMI), smoking status, type II diabetes, aspirin use, alcohol intake, and total energy intake, because these are risk factors for HCC and correlated with nut consumption (see below). Furthermore, alcohol intake often links to coffee consumption, which is a probable protective factor for HCC (28), we also adjusted for total coffee intake.

To maximize the statistical power, we combined two cohorts because we did not detect any statistically significant heterogeneity in the association between total or tree nut consumption and HCC risk by gender. Consistent with the previous study from the same cohorts (20), the trend tests were conducted using the median values of each category of nut consumption as a continuous variable. There was no violation of proportional hazard assumption after testing an interaction term of nut consumption and follow-up time.

Although viral hepatitis is one of the most important risk factors for HCC, we do not have such data in the full cohorts. However, we have conducted three analyses: (i) we evaluated the associations of nut consumption with the risk of HCC according to HBV/HCV infection status (i.e., viral vs. nonviral HCC), and test the potential heterogeneity by these two subtypes; (ii) we excluded HCC cases with known HBV/HCV infections; and (iii) we calculated Spearman correlation coefficients between nut consumption and HBV/HCV infection status among participants with such data to evaluate to what extent the associations might be confounded by HBV/HCV infection status.

Furthermore, we have conducted other sensitivity analyses: (i) we additionally adjusted for tooth loss and periodontal diseases because tooth loss and periodontal diseases might affect nut consumption and might also be associated with liver cancer risk (29); (ii) we adjusted for intake of PUFAs because nuts might improve liver health via being a good food source of PUFAs (30); (iii) we adjusted for one of the most commonly used dietary pattern (i.e., AHEI-2010); (iv) we evaluated each nut consumption in relation to HCC by a history of cirrhosis status (i.e., cirrhosis vs. non-cirrhosis HCC); and (v) we did not adjust for total energy intake in the multivariable analysis as nut consumption is not a major source of total energy intake.

We also conducted exploratory subgroup analyses by age (<70 vs. ≥70 years), BMI (<30 vs. ≥30 kg/m²), smoking status (never vs. ever), type II diabetes (no vs. yes), alcohol consumption (<15 vs. ≥15 g/day), physical activity (<9 vs. ≥9 METS-hours/week), and aspirin use (no vs. yes). All analyses were two-sided and conducted using the SAS Statistical Package (version 9.4, SAS Institute).

Results

After an average of 27.9 years of follow-up, we documented a total of 162 HCC cases (85 in women and 77 in men). Participants with higher total nut consumption were generally leaner, more likely to be physically active and use aspirin, drink alcohol, and less likely to be current smokers (Table 1). Similar patterns were observed for peanuts, tree nuts and walnuts (Supplementary Table S1).

After adjusting for most known HCC risk factors, we observed a nonsignificant inverse association between total nut consumption and HCC risk (the highest vs. lowest tertiles, HR, 0.89; 95% CI, 0.59–0.95) in both men and women. Participants with higher total nut consumption were less likely to be current smokers (Table 1). Similar patterns were observed for peanuts, tree nuts and walnuts (Supplementary Table S1).

After adjusting for most known HCC risk factors, we observed a nonsignificant inverse association between total nut consumption and HCC risk (the highest vs. lowest tertiles, HR, 0.89; 95% CI, 0.59–0.95) for both men and women. Participants with higher total nut consumption were less likely to be current smokers (Table 1). Similar patterns were observed for peanuts, tree nuts and walnuts (Supplementary Table S1).

In sensitivity analyses, although the statistical power was limited because of the number of HCC cases, we did not detect any statistically significant heterogeneity (all P > 0.30) according to HBV/HCV infection status. The results did not appreciably change after excluding HCC cases with HBV/HCV infections with multivariable HRs of 0.92 (95% CI, 0.59–1.43) for total nut and 0.59 (95% CI, 0.38–0.90) for tree nut consumption. In addition, we found nonsignificant associations for total nut consumption after separately adjusting for tooth loss (HR, 0.91; 95% CI, 0.60–1.37), periodontal disease (HR, 0.92; 95% CI, 0.61–1.38), PUFAs (HR, 0.86; 95% CI, 0.57–1.28), and AHEI-2010 (HR, 0.89; 95% CI, 0.59–1.34). Furthermore, we found inverse associations for tree nut consumption, after separately adjusting for tooth loss (HR, 0.67; 95% CI, 0.45–0.99), periodontal disease (HR, 0.68; 95% CI, 0.46–1.01), intake of PUFAs (HR, 0.63; 95% CI, 0.42–0.93), and AHEI-2010 (HR, 0.65; 95% CI, 0.44–0.97). There was no statistically significant heterogeneity in the association between total nut or tree nut consumption and HCC risk according to cirrhosis status (all P > 0.60).
In exploratory subgroup analyses, there were no significant interactions with age, physical activity, smoking, alcohol drinking, type II diabetes, coffee intake, and aspirin use (all \( P > 0.10 \)). Furthermore, among participants who have information on HBV/HCV infection status (including 105 HCC cases and 78 noncases), we found no correlation between nut consumption and HBV/HCV infection status. The Spearman correlation coefficients between HBV/HCV infection and total nut and tree nut consumption were \(-0.05\) and \(0.01\), respectively. Similar results were observed when we calculated the correlations separately among HCC cases and non-HCC cases.

### Discussion

In these two cohort studies with an average of 27.9 years of follow-up, we observed that higher total nut consumption appeared not strongly associated with HCC risk, although there was a suggestive inverse association with tree nut consumption. These findings represent one of the

| Table 1. Characteristics of participants according to intake of total nut consumption in the NHS and HPFS. |
|---------------------------------|---------------------------------|---------------------------------|
| **Women (NHS)**                 | **Men (HPFS)**                  | **Pooled NHS and HPFS cohorts** |
| Age (year)*                     | 67.8 (12.6)                     | 61.1 (11.5)                     |
| White, %                        | 95.2                            | 95.8                            |
| BMI, kg/m²                      | 25.9 (3.6)                      | 25.9 (3.5)                      |
| Physical activity, MET-hours/week| 25.6 (26.7)                     | 25.6 (26.7)                     |
| Type II diabetes, %             | 4.0                             | 4.0                             |
| Regular aspirin use, %          | 26.4                            | 32.2                            |
| Past smoking, %                 | 30.8                            | 34.8                            |
| Current smoking, %              | 4.5                             | 4.8                             |
| Food and nutrient intakes       |                                 |                                 |
| Alcohol, g/day                  | 5.7 (1.2)                       | 5.8 (1.3)                       |
| Total coffee intake, cups/day   | 9.2 (13.1)                      | 10.9 (13.6)                     |
| Peanuts, serving/week           | 0.10 (0.14)                     | 0.52 (0.29)                     |
| Tree nuts, serving/week         | 0.07 (0.12)                     | 0.41 (0.29)                     |
| Walnuts, serving/week           | 0.06 (0.39)                     | 0.18 (0.51)                     |
| Peanut butter, serving/week     | 1.2 (2.2)                       | 1.4 (2.1)                       |
| Polyunsaturated fat, (% of energy) | 5.7 (1.2)                     | 5.8 (1.1)                       |
| **NOTE:** Values were means (SD) or percentages and were standardized to the age distribution of the study population. |
| Value was not age adjusted.     |                                 |                                 |

---

Sui et al.  
Cancer Prev Res; 12(6) June 2019  
Cancer Prevention Research
first prospective epidemiologic studies on the topic and add to the existing data on nut consumption on certain disease risk.

Previous epidemiologic studies, although very limited, have examined associations between nut consumption and certain gastrointestinal cancers with mixed results. The Netherlands Cohort Study showed that increased total nut consumption (>10 g/day vs. nonconsumers) was significantly associated with lower risk of gastric noncardia adenocarcinoma (HR, 0.73; 95% CI, 0.55–0.97; ref. 31), esophageal squamous cell carcinoma (HR, 0.54; 95% CI, 0.30–0.96; ref. 31), and pancreatic cancer (HR, 0.54; 95% CI, 0.30–0.96; ref. 32), but not with risk of gastric cardia adenocarcinoma (HR, 0.91; 95% CI, 0.56–1.49; ref. 31), or esophageal adenocarcinoma (HR, 1.19; 95% CI, 0.74–1.91; ref. 31). The NIH-AARP Diet and Health Study reported inverse association between nut consumption (over a half cup vs. nonconsumers) and gastric noncardia adenocarcinoma (HR, 0.73; 95% CI, 0.57–0.94), but null association for esophageal squamous cell carcinoma (HR, 1.01; 95% CI, 0.66–1.55; ref. 33). In contrast, the Goestaken Cohort Study showed inverse association between nut consumption (top vs. bottom tertiles) and risk of esophageal squamous cell carcinoma (HR, 0.60; 95% CI, 0.39–0.93; ref. 34). Moreover, in the NHS and HPFS cohorts, we reported inverse associations between nut consumption (>2 times/week vs. never) and risk of colorectal cancer (HR, 0.87; 95% CI, 0.72–1.05; ref. 35), and pancreatic cancer (HR, 0.73; 95% CI, 0.54–0.99; ref. 36). Beyond cohort studies, one case-control study reported inverse association between nut consumption (>3 servings per week vs. nonconsumers) and risk of colorectal cancer in women (OR, 0.30; 95% CI, 0.15–0.60) and men (OR, 0.28; 95% CI, 0.17–0.47; ref. 37). The other one found null association with gastric cancer (top vs. bottom tertiles, HR, 0.9; 95% CI, 0.3–3.3; ref. 38). Differences in nut intake levels, confounding control, and number of cases may partially explain some of the observed differential associations.

Although our study did not support a strong association between total nut consumption and HCC risk, most associations were inverse and there was suggestive possible benefit of tree nuts. These results may be due to chance. Alternatively, it is plausible that higher nut consumption might influence HCC risk through mechanisms related to insulin resistance, hyperinsulinemia, and inflammation. Higher consumption of total nuts (39), tree nuts (40), and walnuts (41), was associated with lower risk of type II diabetes, a risk factor for HCC, as well as inversely associated with insulin levels (42). Moreover, nut consumption was associated with weight loss (43) and reduced risk of NAFLD (44). Obesity and NAFLD,
established risk factors for HCC (45, 46), are strongly associated with insulin resistance (47, 48).

Nut consumption might also influence HCC risk via its possible role in improving inflammation and lipid profiles. Persistent inflammation could increase the risk and accelerate the development of HCC (49). In the NHS and HFPS cohorts, intakes of tree nuts and peanuts were both inversely associated with circulating inflammatory markers (CRP, tumor necrosis factor receptor 2, and IL6; ref. 50). Similarly, inverse associations between higher nut consumption and circulating levels of CRP, IL6 were also reported from other prospective cohort studies (10). In addition, cholesterol overload in the liver induces profound cellular redox imbalances and may exert an oxidative stress-mediated effect, and promote the development of HCC (51). Higher nut consumption was linked to lower levels of total cholesterol (52), thereby possibly influencing HCC risk via its influence on lipid profiles. Furthermore, other bioactive compounds contained in nuts, such as vitamins, polyphenols, phytosterols, and selenium may also play a role, which requires further investigation. The reason why most associations were nonsignificant in this study may partly be because of the limited number of HCC cases. Interestingly, because nuts can be a source of aflatoxin exposure, the overall inverse associations between nut consumption and HCC risk suggest that participants in this study are less likely to be exposed to high levels of aflatoxins (53, 54), one of the most known potent hepatocarcinogens.

The strengths of this study include its prospective design, repeated measurements of detailed dietary and lifestyles, validated HCC outcome, and high rates of follow-up. Our study has some limitations. Our study populations were primarily white health professionals and the results may not be generalizable to other racial/ethnic groups. Although FFQs used in these cohorts have shown reasonable reproducibility and validity (21), self-reported diet and lifestyle data have potential measurement errors, as with any observational study. Although we examined peanuts, tree nuts, and walnuts separately, we were unable to examine other tree nuts such as hazelnuts, almonds, macadamias, pecans, cashews, and pistachios. Information on chronic HBV/HCV infection status was not available in the entire cohorts. So, we were unable to conduct analyses adjusting for or stratifying by HBV/HCV infection status in the full cohort analysis. However, among a subset of participants in which HBV/HCV data are available, there was no correlation with nut consumption. Previous studies also suggested no correlations between smoking status, alcohol and coffee intake, obesity, and HBV/HCV infections (26, 55, 56). In addition, we observed similar results when HCC cases with these infections were excluded. Thus, our results were less likely to be substantially confounded by HBV/HCV infections.

In conclusion, we did not observe a strong association between nut consumption and HCC risk, although most associations were inverse and there was suggestive benefit for tree nuts. Our findings should be interpreted with caution, given the limited number of HCC cases and lack of data on HBV/HCV infections in the full cohorts. Future studies should carefully consider HBV/HCV infections and examine the associations in other racial/ethnic groups.

Disclosure of Potential Conflicts of Interest

J.A. Meyerhardt is a consultant/advisory board member for Taiho, Ignyta, and COTA. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: J. Sui, E.L. Giovannucci, X. Zhang
Development of methodology: J. Sui, X. Zhang
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.L. Giovannucci, A.T. Chan, X. Zhang
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J. Sui, W. Yang, Y. Ma, T.Y. Ji, J.A. Meyerhardt, G. Liang, E.L. Giovannucci, X. Zhang
Writing, review, and/or revision of the manuscript: J. Sui, W. Yang, T.G. Simon, J.A. Meyerhardt, G. Liang, E.L. Giovannucci, A.T. Chan, X. Zhang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Sui, A.T. Chan, X. Zhang
Study supervision: A.T. Chan, X. Zhang

Acknowledgments

This research was supported by the UM1 CA186107 (Nurses’ Health Study infrastructure grant), P01 CA87969 (Nurses’ Health Study program grant for cancer research), UM1 CA167552 (Health Professionals Follow-up Study infrastructure grant), NIH K24 DK093811 (to A.T. Chan), and NIH KO7 CA188126 (to X. Zhang). This work was also supported by the American Cancer Society Research Scholar Grant (RSG130476 to X. Zhang) and Boston Nutrition Obesity Research Center Pilot and Feasibility Award (to X. Zhang). A.T. Chan is a Stuart and Suzanne Steele MGH Research Scholar. We would like to thank the participants and staff of the Nurses’ Health Study and the Health Professionals Follow-up Study for their valuable contributions, as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WV. The authors assume full responsibility for analyses and interpretation of these data.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 2, 2019; revised March 20, 2019; accepted April 23, 2019; published first April 30, 2019.
References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

2. Schottenfeld D, Fraumeni JF. Cancer epidemiology and prevention. Oxford, United Kingdom: Oxford University Press. 2006.

3. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Etryson B, et al. Annual report to the Nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst 2017;109:dx30.

4. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391:1301–14.

5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132: 2557–76.

6. Kuper H, Tzonou A, Lagiou P, Mucci LA, Trichopoulos D, Stuver SO, et al. Diet and hepatocellular carcinoma: a case-control study in Greece. Nutr Cancer 2000;38:6–12.

7. Ros E. Health benefits of nut consumption. Nutrients 2010;2: 652–82.

8. Ros E, Hu FB. Consumption of plant seeds and cardiovascular health: epidemiological and clinical trial evidence. Circulation 2013;128:553–65.

9. Rajaram S, Sabate J. Nuts, body weight and insulin resistance. Br J Nutr 2006;96:579–86.

10. Jiang R, Jacobs DR Jr, Mayer-Davis E, Szkel M, Herrington D, Jenny NS, et al. Nut and seed consumption and inflammatory markers in the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006;163:222–31.

11. Aleksandrova K, Bamia C, Droegan D, Lagiou P, Trichopoulou A, Jenab M, et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015;102:498–508.

12. Chen W, Wang JB, Abnet CC, Dawsey SM, Fan JH, Yin LY, et al. Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2015;24:386–92.

13. Kim Y, Keogh JB, Clifton PM. Benefits of nut consumption on insulin resistance and cardiovascular risk factors: multiple potential mechanisms of actions. Nutrients 2017;9:1271.

14. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–8.

15. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54:533–9.

16. Belanger C, Speizer FE, Hennekens CH, Rosner B, Willett W, Bain C. The Nurses’ Health Study: current findings. Am J Nuts 1980;80: 1333.

17. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, et al. A prospective study of nutritional factors and hypertension among US men. Circulation 1992;86:1475–84.

18. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985; 122:51–65.

19. Bao Y, Fan J, Hu FB, Giovannucci EL, Stampfer MJ, Willett WC, et al. Association of nut consumption with total and cause-specific mortality. N Engl J Med 2013;369:2001–11.

20. Guasch-Ferre M, Liu X, Malik VS, Sun Q, Willett WC, Manson JE, et al. Nut consumption and risk of cardiovascular disease. J Am Coll Cardiol 2017;70:2519–32.

21. Salvini S, Hunter DJ, Sampson L, Stampfer MJ, Colditz GA, Rosner B, et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol 1989;18:585–67.

22. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr, Montoye HJ, Sallis JF, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71–80.

23. Chivere SE, Fung TT, Rimm EB, Hu FB, McCullough ML, Wang M, et al. Alternative dietary indices both strongly predict risk of chronic disease. J Nutr 2012;142:1009–18.

24. Rahmani J, Milajerdi A, Dorosty-Motlagh A. Association of the Alternative Healthy Eating Index (AHEI-2010) with depression, stress and anxiety among Iranian military personnel. J R Army Med Corps 2018;164:87–91.

25. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol 1994;140:1016–9.

26. Petrick JL, Campbell PT, Koshol J, Thistle JE, Andreotti G, Beane-Freeman LE, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. Br J Cancer 2018;118:1005–12.

27. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 1997;65:1220S–8S.

28. World Cancer Research Fund/ American Institute for Cancer Research. Diet, nutritional activity and cancer: A Global Perspective. Continuous Update Project Expert Report. 2018. Available at dietandcancerreport.org.

29. Yang B, Petrick JL, Abnet CC, Graubard BI, Murphy G, Weinstein SJ, et al. Tooth loss and liver cancer incidence in a Finnish cohort. Cancer Causes Control 2017;28:899–904.

30. Burns JL, Nakamura MT, Ma DWL. Differentiating the biological energy costs of human physical activities. Med Sci Sports Exerc 2018, 50(12):2453–63.

31. World Cancer Research Fund/ American Institute for Cancer Research. Diet, nutritional activity and cancer: A Global Perspective. Continuous Update Project Expert Report. 2018. Available at dietandcancerreport.org.

32. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr, Montoye HJ, Sallis JF, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71–80.

33. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, et al. A prospective study of nutritional factors and hypertension among US men. Circulation 1992;86:1475–84.

34. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985; 122:51–65.

35. Bao Y, Fan J, Hu FB, Giovannucci EL, Stampfer MJ, Willett WC, et al. Association of nut consumption with total and cause-specific mortality. N Engl J Med 2013;369:2001–11.

36. Guasch-Ferre M, Liu X, Malik VS, Sun Q, Willett WC, Manson JE, et al. Nut consumption and risk of cardiovascular disease. J Am Coll Cardiol 2017;70:2519–32.

37. Salvini S, Hunter DJ, Sampson L, Stampfer MJ, Colditz GA, Rosner B, et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol 1989;18:585–67.

38. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr, Montoye HJ, Sallis JF, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71–80.
38. Wang XQ, Yan H, Terry PD, Wang JS, Cheng L, Wu WA, et al. Interaction between dietary factors and Helicobacter pylori infection in noncardia gastric cancer: a population-based case-control study in China. J Am Coll Nutr 2012;31:375–84.
39. Jiang R, Manson JE, Stampfer MJ, Liu S, Willett WC, Hu FB. Nut and peanut butter consumption and risk of type 2 diabetes in women. JAMA 2002;288:2554–60.
40. Mohan V, Gayathri R, Jaacks LM, Lakshmipriya N, Anjana RM, Spiegelman D, et al. Cashew nut consumption increases HDL cholesterol and reduces systolic blood pressure in Asian Indians with type 2 diabetes: a 12-week randomized controlled trial. J Nutr 2018;148:63–9.
41. Pan A, Sun Q, Manson JE, Willett WC, Hu FB. Walnut consumption is associated with lower risk of type 2 diabetes in women. J Nutr 2013;143:512–8.
42. Sauder KA, McCrea CE, Ulbrecht JS, Kris-Etherton PM, West SG. Effects of pistachios on the lipid/lipoprotein profile, glycemic control, inflammation, and endothelial function in type 2 diabetes: a randomized trial. Metabolism 2015;64:1521–9.
43. Tan SY, Dhillon J, Mattes RD. A review of the effects of nuts on appetite, food intake, metabolism, and body weight. Am J Clin Nutr 2014;100:412S–22S.
44. Han JM, Jo AN, Lee SM, Bae HS, Jun DW, Cho YK, et al. Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2014;29:1265–72.
45. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012;56:704–13.
46. Streba LA, Vere CC, Rogueanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015;21:4103–10.
47. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013;5:1544–60.
48. Ye J. Mechanisms of insulin resistance in obesity. Front Med 2013;7:14–24.
49. Bishaye A. The role of inflammation and liver cancer. Adv Exp Med Biol 2014;816:401–35.
50. Yu Z, Malik VS, Keum N, Hu FB, Giovannucci EL, Stampfer MJ, et al. Associations between nut consumption and inflammatory biomarkers. Am J Clin Nutr 2016;104:722–8.
51. Enriquez-Cortina C, Bello-Monroy O, Rosales-Cruz P, Souza V, Miranda RI, Toledo-Perez R, et al. Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis. Oncotarget 2017;8:104136–48.
52. Mukuddem-Petersen J, Oosthuizen W, Jerling JC. A systematic review of the effects of nuts on blood lipid profiles in humans. J Nutr 2005;135:2082–9.
53. Diella G, Caggiano G, Ferrieri F, Ventrella A, Palma M, Napoli C, et al. Aflatoxin contamination in nuts marketed in Italy: preliminary results. Ann Ig 2018;30:401–9.
54. Petrick JL, Freedman ND, Graubard BI, Sahasrabuddhe VV, Lai GY, Alavanja MC, et al. Coffee consumption and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by sex: The Liver Cancer Pooling Project. Cancer Epidemiol Biomarkers Prev 2015;24:1398–406.
55. Campbell PT, Newton CC, Freedman ND, Koshiol J, Alavanja MC, Beane Freeman LE, et al. Body mass index, waist circumference, diabetes, and risk of liver cancer for U.S. Adults. Cancer Res 2016;76:6076–83.